30 Evaluation of trends of neoadjuvant therapy for Breast Cancer using Joinpoint

Oregon Convention Center 

Neoadjuvant therapy is on the rise to treat HER2-Positive breast cancer. However, there is no study evaluates the trend of neoadjuvant in the past decade.
In this study, we included breast cancer patients ≥18 years diagnosed with stage I to III HER2-positive breast cancer who received chemotherapy, and surgery from the Surveillance, Epidemiology, and End Results Program from 2010 to 2020. Joinpoint models were used to assess trends in neoadjuvant treatment and association of patients' characteristics and neoadjuvant treatment was evaluated by generalized estimating equations.
A total of 59,965 women with median age of 56 years, 60.9% were White, 14.5% were Hispanic, 11.9% were Asian, 11.6% were Black, and 1% were other or unknow race ethnicity. Neoadjuvant chemotherapy was increased from 20.1% to 46.1% between 2010-2020 (p-value <.001). Neoadjuvant increased the most in stage I patients with the average annual percent change (AAPC) of 22 with 95% confidence interval (CI) of (18-26.2) followed by 10.1 (8.5-11.8), and 4.4 (2.0-7.0) for stage II and III respectively. Neoadjuvant therapy for HER2-Positive EBC increases and its survival effects need to be evaluated.

trend

joinpoint

breast cancer 

Section on Statistics in Epidemiology